RxDoctor Payments Data

Kaylee Day, MD

Family Medicine · Tallahassee, FLNPI 1376156653

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 64 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$222
  • AbbVie$216
  • Amgen$171
  • Pfizer$136
  • Novo Nordisk$120
  • Bayer$78
  • plus $453 from 13 others

What the payments were for

  • Food & beverage$1,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,068
Medicare patients
12
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$17,254
EliquisApixaban22$16,807
FarxigaDapagliflozin Propanediol13$9,455
LantusInsulin Glargine,hum.Rec.Anlog11$694
Atorvastatin Calcium54$455
Duloxetine Hcl16$344
Irbesartan16$301
Omeprazole16$278
Losartan Potassium23$210
Gabapentin18$199
Amlodipine Besylate36$186
Chlorthalidone11$164
Levothyroxine Sodium17$158
Carvedilol16$116
Ezetimibe12$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$72$17,25415 claims
PfizerEliquis$136$16,80722 claims
AstraZenecaFarxiga$222$9,45513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →